

First UK site goes live in global Alzheimer's disease clinical trial

- First UK trial site opens for patient enrolment into XanADu – Actinogen's clinical trial evaluating Xanamem™ in Alzheimer's disease
- UK patients can now be enrolled and treated
- This marks a significant milestone, with XanADu research sites now open in all three countries - Australia, the US and the UK
- Ten of the 20 global trial sites (50%) are now open for patient recruitment
- Opening this UK site reflects continued good momentum for the trial and follows the first patient being dosed in Australia in May 2017

Sydney, 1 June 2017: Actinogen Medical (ASX: ACW) is pleased to announce that its first UK site has opened, for patient recruitment into its clinical trial XanADu, the Company's study of Xanamem in the treatment of Alzheimer's disease.

This marks another significant milestone for Actinogen Medical as XanADu research sites are now active for patient recruitment in all three countries where the trial is being conducted - Australia, the USA and the UK. Ten of the 20 research sites are now open for patient recruitment, with four in Australia and five in the US.

Patient selection and enrolment will now commence in the UK at the University of Edinburgh Centre for Dementia Prevention, one of the most respected neuroscience institutes globally. It is the first of seven XanADu trial sites planned for the UK and follows the recent announcement of the trial's first patient being dosed in Australia in mid-May 2017.

XanADu is a landmark study in the global search for a new and effective treatment for patients living with Alzheimer's disease. The study is evaluating Actinogen's new research drug Xanamem, which works by blocking the body's excess production of the stress hormone, cortisol. Excess cortisol has been shown to be strongly associated with the development of Alzheimer's disease, and blocking this excess cortisol production in the brain is seen as a promising approach to treating the disease.

"I am extremely pleased that patients in the UK will finally have the opportunity to receive this experimental treatment for Alzheimer's disease" said Professor Craig Ritchie, Professor of the Psychiatry of Aging and Director of the Centre for Dementia Prevention at the University of Edinburgh. "It is also particularly pleasing to evaluate Xanamem as a potential treatment for Alzheimer's disease, as it's a drug discovered at Edinburgh University", he said.

Dr Bill Ketelbey, CEO of Actinogen Medical commented: "We are very pleased with the ongoing progress of XanADu, our Alzheimer's disease clinical trial, and with the opening of our first UK clinical site. It is a significant milestone for Actinogen Medical and for patients living in the UK with Alzheimer's disease, with 50% of the trial sites now open for patient recruitment, including the first UK site."

XanADu is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the location of study sites open for patient recruitment.

ENDS

Actinogen Medical

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

Media Enquires

Andrew Ramadge

Media & Capital Partners

M: +61 475 797 471

E: andrew.ramadge@mcpartners.com.au

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem, in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. Patient recruitment into XanADu began in Q2 2017 – topline results are expected in Q1 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.